The panelists continued to discuss evidence-based medicine, as well as the incentives there might be to examine emerging and existing therapies or drugs.
The panelists continued to discuss evidence-based medicine, as well as the incentives there might be to examine emerging and existing therapies or drugs.
Dr Yu revisited the difference between findings that are presented in studies, as they compare to finding in real-world settings. He said assumptions about “best regimens” should be tested to determine patient response. Drugs and patient outcomes should be continually monitored, even after gaining FDA approval.
Dr Marlin said pathway programs can motivate drug or therapy manufacturers to expand development of evidence-based medicines. She thought that the current shift in treatment decision-making will incentivize developers to invest in evidence-based medicine.
Dr Nabhan said literature focuses too strongly on efficacy. Certain measures, such as hospitalizations, cannot be observed in small clinical trials.
Dr Tischler agreed, saying that many decisions should be made based on real-world setting data and observations.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More